| Reduced Risk Status: |
|
| IPM Compatibility: |
PER REQUESTER: GOOD IPM FIT; USE PATTERN FOR THE FUNGICIDE WOULD BE AS A DRENCH SO IMPACT ON BIOLOGICAL CONTROL AGENTS IS EXPECTED TO BE MINIMAL
|
| Reasons for need: |
FUSARIUM; VERY LIMITED NUMBER OF FUNGICIDES REGISTERED FOR FUSARIUM CONTROL ON GH CUCUMBERS; PER ME-TOO REQUEST FROM ME: NEED MORE DISEASE CONTROL TOOLS IN THE GH, AND THIS LOOKS LIKE A GOOD FIT
|
| Requesting State(s): |
CA:Ingersoll, T, Sfetcu, D ; MS:Henn, A ; NC:Wrenn, A ; OH:Tifft, K ; TX:Bledsoe, M ; UT:Sfetcu, D ;
|
| PCR Use Pattern: |
USE THE MIRAVIS PRIME PRODUCT; MAKE TWO DRENCH APPLIC OF 125 G AI/HA, 14-DAY INTERVAL, 0-DAY PHI
|
| EPA Default Residue Trials: |
ANY 4 TRIALS
|
| IR-4 Residue Trial Plan: |
ANY 4 TRIALS
|
| Residue Protocol Use Pattern: |
USE THE MIRAVIS PRIME PRODUCT (1.25 LB AI OF PYDIFLUMETOFEN AND 2.09 LB AI OF FLUDIOXONIL ACTIVE INGREDIENTS/GAL OF PRODUCT); MAKE 2 DRENCH APPLIC OF 15.4 FL OZ PRODUCT/A (0.150 LB AI/A OF PYDIFLUMETOFEN + 0.251 LB AI/A OF FLUDIOXONIL), 14-DAY INTERVAL, 0-DAY PHI; APPLY 236 TO 590 ML OF DILUTED SOLUTION/1 SQ FT OF SURFACE AREA TREATED
|
| Efficacy/Crop Safety (E/CS) Data Required: |
|
| E/CS Research Comments: |
IN THE PERFORMANCE PROTOCOL FOR 2022: EVALUATING PRODUCT PERFORMANCE ON COMMERCIAL VARIETIES SUSCEPTIBLE TO FUSARIUM WILT; TESTING SOIL DRENCH APPLIC OF 15.4 FL OZ/A OF MIRAVIS PRIME (PYDIFLUMETOFEN + FLUDIOXONIL) VS A LABELED RATE OF A STANDARD (APPLY PER LABEL DIRECTIONS); MAKE 2 DRENCH APPLC OF MIRAVIS PRIME, WITH 1ST APPLIC 2-4 WEEKS AFTER TRANSPLANTING, AND 2ND APPLIC 14 DAYS LATER; APPLY 236-590 ML OF DILUTED SOLUTION/1 SQ FT OF SURFACE AREA TREATED; EVALUATE FUSARIUM WILT DISEASE INCIDENCE AND SEVERITY, CROP SAFETY AND CROP YIELD; THE 2023 AND 2024 PERFORMANCE PROTOCOLS FOLLOW THE APPLIC AND EVALUATION REQUIREMENTS OF THE 2022 PROTOCOL
|
| Label Use Pattern Submitted To EPA: |
|
| EPA PIF Status: |
GREEN (BOTH):09/19, 08/20, 08/21
|
| EPA Status: |
|
| EPA PRIA Date: |
|
| MRID: |
|
| Comments: |
CANADA IS NOTED AS A KEY EXPORT MARKET; NEED TO EXPLORE USE OF EXISTING RESIDUE STUDIES IN CANADA (ON FLUDIOXONIL) AND IR-4 (PYDIFLUMETEFON, PR# 11156, ONLY 3 GH TRIALS DONE) TO COVER THE NEED IN THE U.S.; ALSO, SEE PR# 12008 (FLUDIOXONIL/GH CUCUMBER); USE PATTERN MUST BE CONSISTENT FOR BOTH COUNTRIES (DRENCH VS FOLIAR DATA, # OF APPLIC, INTERVAL AND PHI, ETC.):01/19; CANADA CONFIRMED THERE IS NO GH STUDY, SO STATUS CHANGED TO RESIDUE RESEARCHER:05/19; EPA GREEN (BOTH):09/19; MFG CONFRIMED E/CS DATA ARE ALSO NEEDED TO SUPPORT THIS GH USE:05/20; EPA GREEN (BOTH): 08/20, 08/21; ASR RECD FOR FLUDIOXONIL, AWAITING ASR FOR PYDIFLUMETOFEN: 11/23, JPB; Still awaiting performance data. 1/24 DRS; 2024 performance protocol signed 05/24/drs;
|
| International Status: |
|
| Archive Location: |
|
| QA Archive: |
|